Upgrade to SI Premium - Free Trial

Sola Failures Appears 'Near-Perfect' for Biogen (BIIB) - Stifel

November 23, 2016 8:40 AM
Stifel analyst Thomas Shrader weighed in on Biogen (NASDAQ: BIIB) Eli Lilly's Solanezumab did not meet its primary endpoint in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments FDA Trader Talk

Next Articles